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Program Director and Resident Perspectives on New Parent Leave in Dermatology Residency
New parent leave (NPL) has been defined as leave from work for all parents after welcoming a child regardless of how they became parents (including giving birth to a child, adoption, surrogacy, or fostering). New parent leave is essential for the wellbeing of the infant and family. Of note, the United States and Papua New Guinea are the only 2 nations in the world that do not have statutory paid leave. 1 A study reported that 64.1% of dermatology residents are women, most of childbearing age. 2 A recent survey found that female dermatologists were most likely to have a child during residency (51%) compared with during other stages of their training and career. 3 Residents have a finite time to learn their medical specialty and are subject to rules of the American Board of Dermatology (ABD) 4 and varying institution-specific policies for absences during their training. The goal of our work was to investigate how NPL is currently handled in dermatology residency programs and how the policies are perceived by program directors (PDs) and residents. For the resident survey, of the 139 responders, 98 (70.5%) were women, 40 (28.8%) were men, and 1 (0.7%) was a person of nonbinary gender. The mean (SD) age of residents at the beginning of residency was 27.8 (2.3) years (range, 24-39 years). Of the responding residents, 37 (29.8%) became parents during residency.
As indicated in Table 1 , the 12 residents who were pregnant and gave birth to a child took a mean (SD) leave of 6.8 (2.6) weeks (range, 4-14 weeks). One resident was active duty military and took 14 weeks, which was the longest reported in the study; the military guarantees 12 weeks paid leave. The 6 male residents who became new parents had a mean (SD) leave of 2.0 (2.6) weeks (range, 0-8 weeks). Resident and PD perceptions of NPL are presented in Table 2 .
Discussion | We observed significant variation among dermatology residency programs for how NPL was handled. Many PDs commented that a lack of clarity on the rules from the ABD results in variable lengths of leave, usually erring on very short leaves. The number of male and female residents who reported their length of leave was low (n = 18), possibly be- cause of survey question fatigue or concern about negative consequences for themselves, the program, or future parents. We were struck by the baseline lack of awareness by residents of NPL policies despite most programs having policies in place. We also noticed a discrepancy between PDs and residents when it came to opinions of sufficiency of NPL and pumping facilities. A limitation of our study was an inability to determine which programs were being represented by the deidentified PD and resident surveys. Our findings suggest that residency programs and the ABD should examine and clarify NPL policies for residents to ensure that they support new parents and safeguard their physical and mental health as well as career development. Abbreviation: NA, not applicable.
Letters
OBSERVATION
Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid
Bullous pemphigoid (BP) is a pruritic autoimmune blistering disorder that most commonly affects elderly patients. Therapeutic options have limitations based on effectiveness, adverse effects, and patient comorbidities. We present a case of an elderly man with bullous pemphigoid successfully treated with dupilumab, an interleukin (IL)-4 alpha antagonist.
Report of a Case | A man in his 80s presented with a 6-week history of progressive pruritic tense bullae distributed over the trunk and extremities, with sparing of mucosal surfaces. The patient denied taking any new medications. Lesional and perilesional biopsies were performed, which revealed eosinophil-and neutrophil-rich subepidermal bullae with 3+ linear IgG immunoreactivity along the dermal-epidermal junction. A diagnosis of BP was made, and the patient started treatment with a prednisone taper. After 2 flares during tapering of prednisone (Figure, A) , the decision was made to proceed with immunomodulatory treatments. However, screening laboratory results were positive for Mycobacterium tuberculosis and hepatitis B core antibody. Given the patient's severe disease status and treatment limitations, his treatment was transitioned to a therapeutic trial of dupilumab, with an initial loading dose of 600 mg administered subcutaneously followed by weekly 300-mg subcutaneous injections. The patient noted improvement in his itch within a week after his first injection but continued to develop blisters in the first month.
After 3 months of dupilumab therapy, the patient had resolution of all blisters (Figure, B) and undetectable levels of BP180 and BP230 antibodies. At last follow-up, after 10months of dupilumab monotherapy, he remained clear of lesions.
Discussion | Treatment of BP can be challenging, especially in refractory cases. Oral corticosteroids are the most common initial therapy for BP, but they are not ideal for long-term treatment owing to their adverse effect profile. 1 Alternative agents with reported efficacy include azathioprine, mycophenolate mofetil, methotrexate, cyclosporine, cyclophosphamide, rituximab, dapsone, plasma exchange, and antibiotics. 1 Patients with BP have an increased number of IL-4-and IL-13-producing cells in the blood serum and blister fluid, a majority of which are cutaneous lymphocyte antigen positive, and these numbers decrease during treatment.
2 Dupilumab targets both IL-4 and IL-13 and is also a potent inhibitor of chemokines associated with helper T cell, type 2 (chemokine [C-C motif] ligand 17 [CCL17], CCL18, CCL22, and CCL26). 3 Levels of CCL18 are 5-fold and 7-fold higher in the blister fluid of patients with BP than in the blood serum of patients with BP and healthy individuals, respectively, and these increased levels correlate with the disease course in most patients. 4 Furthermore, IL-4 is involved in classswitching in B cells, suggesting a mechanism of action for dupilumab in the treatment of BP. 
